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Early Diagnosis of Primary Human Herpesvirus 6 Infection in Childhood:
Serology, Polymerase Chain Reaction, and Virus Load
Susan S. Chiu, C. Y. Cheung, Catherine Y. C. Tse, and
Malik Peiris
Departments of Pediatrics and Microbiology,
University of Hong Kong
Qualitative and quantitative polymerase chain reaction (PCR) for human herpesvirus 6
(HHV-6) DNA in whole blood and plasma was correlated with serology and clinical assess-
ment in 143 children hospitalized for undifferentiated febrile illness to evaluate options for
diagnosis of primary HHV-6 infection on the acute blood specimen. PCR and serology for
HHV-7 were done in parallel to define serologic cross-reactions. Using HHV-6 seroconversion
as the reference standard, detection of HHV-6 DNA in whole blood in the absence of antibody
in the plasma was the most reliable evidence of primary HHV-6 infection. Detection of HHV-
6 DNA in plasma and a high virus load in whole blood (13.3 log10 copies/5 mL) had a sensitivity
of 90% and 100%, respectively, in diagnosing primary HHV-6 infection. However, both were
occasionally found in patients with other infections, possibly associated with HHV-6 reacti-
vation. Maternal antibody may confound interpretation of serology in patients under 3
months of age.
Human herpesvirus 6 (HHV-6) is a common infection in
childhood. Primary infection usually occurs during infancy [1],
and 76%–92% of children are seropositive by the age of 1 year
[2]. Primary infection is associated with the syndrome roseola
infantum or exanthem subitum [3], an acute febrile illness fol-
lowed by a maculopapular rash appearing with defervescence.
Clinically, this diagnosis becomes apparent only in retrospect
with the appearance of the rash. Furthermore, the typical pre-
sentation of roseola is seen only in a proportion of patients,
and the full clinical spectrum of primary HHV-6 infection is
still being elucidated. In one study, it accounted for 20% of
visits to pediatric emergency services for febrile illness in chil-
dren 6–12 months of age [4]. The majority of these patients did
not present with classical roseola, and at presentation to pe-
diatric outpatient or inpatient services, a wide range of differ-
ential diagnoses were considered, including otitis media, sepsis,
and meningoencephalitis. Furthermore, many children clini-
cally diagnosed to have measles or other exanthems in fact have
HHV-6 infections [5].
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The only options for laboratory diagnosis available at pre-
sent are the demonstration of rising antibody titers (for which
paired specimens of blood are required) and culture of the virus
from peripheral blood mononuclear cells [3]. In both instances,
the diagnosis is retrospective. Furthermore, viral culture for
HHV-6 requires cocultivation with cord blood mononuclear
cells and is not practicable in a routine diagnostic laboratory
setting. Antibody avidity has been investigated for the diagnosis
of primary HHV-6 infection, but since antibody is not detect-
able in specimens collected within the first 5 days after onset
of illness, it is only applicable in convalescent sera or those
collected later in the illness [6]. Similarly, IgM antibody detec-
tion has thus far not proved to be sensitive and specific enough
for routine diagnosis when applied to the acute blood specimen.
More than 25% of serum specimens collected at initial presen-
tation may be negative for HHV-6 IgM antibody [7]. Typically,
the IgM response develops 5–7 days after onset of the disease.
Detection of viral DNA in plasma by polymerase chain re-
action (PCR) has been reported previously as a diagnostic op-
tion [8, 9]. However, in the study by Huang et al. [8], only a
minority of patients with acute HHV-6 infection had viral DNA
detected in the acute plasma specimen, although the convales-
cent specimen was always positive. The study by Secchiero et
al. [9] investigated few ( ) pediatric patients, and details onn 5 7
timing of specimens in relation to onset of disease was not
reported. Thus, the sensitivity, specificity, and predictive value
of plasma DNA detection in the diagnosis of primary HHV-6
infections remain undefined at present. A recent study [10] has
investigated qualitative and quantitative PCR in peripheral
blood leukocytes (PBL) and saliva for the diagnosis of primary
HHV-6 infection. However, they rely on the yet-unproved hy-
pothesis that detection of viral HHV-6 DNA in PBL in the
absence of HHV-6 DNA in saliva indicates primary HHV-6
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infection. None of the 3 patients had the diagnosis of primary
HHV-6 infection confirmed by seroconversion or viral culture.
The aim of the present study was to define laboratory pa-
rameters that can be used to diagnose primary HHV-6 infection
by testing the acute specimen (within 5 days of disease onset)
collected at the time of initial presentation.
The hypotheses being tested were that in the acute blood
specimen, the following were predictive of primary HHV-6 in-
fection: detection of HHV-6 DNA in plasma, a profile of de-
tectable DNA in whole blood in the absence of IgG antibody
in the plasma, and a higher viral DNA load in the whole blood
specimen. Further, we hypothesized that the HHV-6 DNA/IgG
profile of the acute blood specimen would correlate with in-
fection status in the following way: HHV-6 DNA detected in
whole blood in the absence of HHV-6 IgG in plasma correlates
with primary HHV-6 infection, positive HHV-6 IgG (irrespec-
tive of viral DNA result) is indicative of past HHV-6 infection,
and a negative result for both HHV-6 DNA and IgG indicates
the absence of infection (past or present).
Methods
Patients. Children aged ≤3 years admitted (to the general pe-
diatric ward of a teaching hospital) with fever (138.07C) of !5 days’
duration were eligible for recruitment to the study. Patients with
an obvious bacterial etiology for fever (e.g., lobar pneumonia, uri-
nary tract infection) at admission were excluded. After discharge
from the hospital, patients were requested to return 2–4 weeks later
for clinical and serologic follow-up. Review of patient charts was
done by one of us (S.S.C.) without prior knowledge of the labo-
ratory results.
Specimens. During routine clinical workup of the patients, an
extra 0.5 mL of blood was drawn into EDTA for the purposes of
HHV-6 and HHV-7 serology and PCR analysis. The specimens
were centrifuged, and 200 mL of plasma was withdrawn and stored
at 2707C. The volume of the remaining blood specimen was re-
constituted by adding back 200 mL of PBS, and the reconstituted
whole blood was stored frozen at 2707C.
DNA was extracted separately from 200 mL of the thawed plasma
and the whole blood specimens with the Qiagen blood kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
When extracting viral DNA from plasma, 0.04 mg of carrier DNA
was added to the 200-mL plasma sample before application to the
QIAamp column. The DNA was eluted into 200 mL of autoclaved
deionized water and stored at 2207C until tested by PCR.
Saliva specimens were collected from some patients at the time
of hospitalization (Salivettes; Sarstedt, Numbrecht, Germany). The
sponge was placed in the mouth for 45 s before being replaced in
the container. Saliva was extracted by centrifugation and stored at
2707C. The saliva was boiled for 10 min, and the centrifuged
supernatant was used for PCR.
PCR for HHV-6 and HHV-7 DNA. The primers used for
HHV-6 [11] and HHV-7 [12] and the nested PCR conditions have
been described previously [13]. DNA extract (5 mL) was amplified
by a nested PCR in a 50-mL reaction mixture containing Taq poly-
merase (Boehringer Mannheim, Mannheim, Germany) and 1.5
mM MgCl. Agarose gel electrophoresis was used to detect the
amplicons of the HHV-6 nested PCR. The identity of the HHV-7
amplicons were confirmed by oligonucleotide hybridization as de-
scribed previously [13], with the modification that a digoxigenin-
labeled probe was used together with a chemiluminescent detection
system (Boehringer Mannheim).
Precautions to exclude cross-contamination during specimen ex-
traction and PCR amplification [14] were strictly adhered to. The
PCR for HHV-6 and HHV-7 did not cross-amplify the genomes
of each other or that of HHV-1 through HHV-5 [13].
Quantitative PCR for HHV-6 DNA. Specimens positive for
HHV-6 DNA in the screening PCR assay were quantitated by an
end-point dilution PCR. Serial 0.5-log dilutions of the DNA ex-
tracts were tested in a single-round hot-start PCR reaction with
the outer PCR primers and Amplitaq Gold (Applied Biosystems,
Foster City, CA). Each PCR run included a dilution series of the
linearized plasmid pH6 [11] equivalent to 3.8, 3.3, 2.8, and 2.3 log10
genome copies. The band intensities of the amplified diluted spec-
imens were compared with those of the standard dilution curve to
estimate the number of genome copies in each sample. Variation
between PCR runs was within 0.5 log10 genome copies. To further
control for variability between PCR runs and make comparisons
between patient and specimen groups more reliable, DNA extracts
of acute and convalescent whole blood and plasma from a patient
with HHV-6 seroconversion were titrated in parallel with DNA
from whole blood of a matched patient with past infection.
The pH6 standard we used was compared with an independent
plasmid pH6 preparation of known genome copy number (from
W. Pumeechockchai, University of Newcastle upon Tyne, UK) and
a quantified preparation of viral DNA extracted from purified
HHV-6 nucleocapsids (provided by P. Pellet, Centers for Disease
Control and Prevention, Atlanta).
Serology for HHV-6 and HHV-7. HHV-6 (AJ strain)–infected
HSB-2 cells and HHV-7 (DC strain)–infected Sup-T1 cells were
used in indirect immunofluorescence assays to detect HHV-6 and
HHV-7 antibodies, respectively [13]. Patients’ plasma specimens
were screened at a dilution of 1/50 by an anti-human IgG conjugate
(Inova, San Diego). In patients with paired specimens, serial 2-fold
dilutions of plasma specimens were titrated in parallel, starting at
a dilution of 1/25. All immunofluorescence results were read by the
same investigator (M.P.).
Other laboratory investigations. The patients were investigated
for other microbiologic causes of febrile illness as clinically indi-
cated. These included examining nasopharyngeal aspirates for viral
antigens by immunofluorescence and other appropriate specimens
for viral and bacteriologic culture.
PCR analysis and serology were carried out blinded to the results
of each other, to other routine laboratory investigations, and to
the clinical assessment of the patient.
Results
One hundred forty-three patients were recruited over an 8-
month period between November 1996 through June 1997.
Paired blood specimens were available from 49 patients. The
remaining 94 patients failed to attend follow-up for convales-
cent specimen collection and were analyzed separately. The pa-
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Figure 1. HHV-6 DNA load (genome copies/5 mL) in whole blood
specimens: comparison of acute and convalescent specimens in primary
and past infections.
Table 1. HHV-6 DNA results on 42 patients 13 months old with paired sera.
Serostatus to HHV-6
HHV-6 DNA–positive
HHV-6 DNA–positive/IgG-negative
in whole blood (acute specimen)
13.3 log10 copies of HHV-6
DNA/5 mL of whole blooda
Seroconversion
to HHV-7In whole blood In plasma
Seroconversion (n 5 20) 20/20 (100) 18/20 (90) 20/20 (100) 20/20 (100) 8/20 (40)
Static titers (n 5 18) 13/18 (72) 0/18 0/18 0/18 0/18
No antibody (n 5 4) 0/4 0/4 0/4 0/4 0/4
NOTE. Data are no./total (%).
a Cutoff value for viral DNA load based on data in figure 1.
tients with paired and single blood specimens were similar in
demographic and clinical parameters: mean age, 12.2 versus
13.6 months ( ); male-to-female ratio, 1.5:1 versus 1.4:1P 5 .3
( ); duration of fever at admission, 2.0 versus 1.8 daysP 5 .7
( ); and mean temperature at presentation, 39.47C versusP 5 .27
39.37C ( ).P 5 .3
To minimize the potential confounding effect of maternal
antibody on serologic responses, patients with paired blood
specimens who were 13 months old at presentation ( )n 5 42
were analyzed initially. Twenty patients had ≥4-fold increases
in antibody titer to HHV-6, 18 patients had static titers to HHV-
6, and 4 patients remained seronegative in both acute and con-
valescent specimens.
Using HHV-6 seroconversion as the reference standard for
diagnosing primary or past HHV-6 infection, we evaluated the
detection of HHV-6 DNA in whole blood, the detection of
HHV-6 DNA in plasma, and the HHV-6 DNA/IgG profile as
methods for providing a reliable diagnosis on the acute spec-
imen at initial clinical presentation (table 1). On the basis of
these results, the sensitivity, specificity, positive predictive value,
and negative predictive value of detecting viral DNA in acute
whole blood for diagnosing primary HHV-6 infection were
100%, 41%, 61%, and 100%, whereas those for DNA in the
acute plasma were 90%, 100%, 100%, and 92%, respectively.
One of the 20 patients with primary infection and another with
past infection had detectable viral DNA in the convalescent
plasma specimen.
The profile of positive HHV-6 DNA in the absence of IgG
in an acute whole blood specimen had sensitivity, specificity,
and predictive values of 100% for diagnosing primary HHV-6
infection.
Quantitation of viral DNA in whole blood and plasma. The
use of hot-start PCR (Amplitaq Gold) in the quantitative PCR
significantly reduced nonspecific amplification bands often seen
when using conventional Taq polymerase enzymes and resulted
in improved sensitivity and specificity of the single-round PCR
reaction, eliminating the need to use nested PCR to confirm
specificity of the PCR reaction. Figure 1 shows the HHV-6
DNA load (genome copies/5 mL) in acute and convalescent
whole blood of patients with HHV-6 seroconversion and past
infection, respectively. In patients with HHV-6 seroconversion,
viral DNA load in the acute whole blood specimen was at least
0.5 log10 greater than that in the convalescent specimen. In
contrast, those patients with serologic evidence of past infection
had a ≤0.5 log10 difference in virus load between acute and
convalescent specimens with 1 exception (the latter being as-
sociated with a 1 log10 increase in the convalescent specimen).
All patients with seroconversion to HHV-6 had 13.3 log10 copies
of HHV-6 DNA/5 mL of acute whole blood, in contrast to those
with past infection (figure 1). This level of virus load differ-
entiated recent from past infection with sensitivity, specificity,
and predictive values of 100% (table 1).
Five patients with primary HHV-6 infection had a third
blood specimen collected between 22 and 29 weeks after onset
of primary infection, at which time viral DNA load in all but
1 patient had fallen to ≤2.8 log10 copies/5 mL of whole blood.
Viral DNA levels in the acute whole blood specimen were
compared with those in the corresponding plasma specimen
(figure 2). Viral DNA levels in whole blood were usually higher
than those in plasma.
Patients !3 months of age. The laboratory findings of the
7 patients !3 months of age whose paired blood samples were
excluded from initial analysis were as follows. Two patients
were seronegative in both acute and convalescent plasma spec-
imens, were PCR-negative for HHV-6 in all specimens, and
were therefore presumed not to have HHV-6 infection. In fact,
1 of them had a confirmed alternative diagnosis of Escherichia
coli urinary tract infection. The remaining 5 patients all had
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Figure 2. Comparison of HHV-6 DNA load (genome copies/5 mL)
in acute whole blood and plasma specimens.
HHV-6 DNA in the acute whole blood DNA extract. Two of
these patients seroconverted to HHV-6, had the HHV-6 DNA/
IgG profile suggestive of primary HHV-6 infection, had high
viral DNA loads in whole blood, and were clinically diagnosed
to have roseola. However, unlike older children whose con-
valescent antibody titers often exceed 1/400, 1 of these young
babies developed only modest antibody titers to the virus (1/
50 at 2 weeks and 1/100 at 27 weeks after infection).
Two other patients remained seronegative in both acute and
convalescent specimens, and 1 other had static antibody titers,
although all 3 had high viral DNA load in the whole blood
(≥4.3 log genome copies/5 mL), had viral DNA in the plasma,
and had a clinical diagnosis of roseola. The overall interpre-
tation of these findings indicates that these 3 patients had pri-
mary HHV-6 infection, even though there was no detectable
serologic response.
Serology to HHV-7. Of the 42 patients 13 months old for
whom paired serum specimens were available, 8 had serocon-
version to HHV-7 and a further 6 had a marginal serologic
response (i.e., !1/25 to 1/25). Only 3 of these patients had HHV-
7 DNA detected in the acute whole blood specimen, 1 of them
also having HHV-7 DNA in the plasma. None of these 3 pa-
tients had HHV-7 IgG in the acute plasma specimen, and their
clinical presentation was that of roseola in 1 and a febrile illness
with diarrhea in the other 2.
All 14 patients had concurrent seroconversion to HHV-6,
had detectable HHV-6 DNA in whole blood in the absence of
IgG, and had high HHV-6 DNA load (13.3 log10/5 mL of whole
blood). Twelve had HHV-6 DNA in the plasma. None of the
patients negative for antibody or with static titers to HHV-6
had a rise in antibody titers to HHV-7.
Patients from whom only a single (acute) blood specimen was
available. Eighty-nine of the 94 patients from whom paired
specimens were unavailable were 13 months of age. Of them,
14 had detectable HHV-6 DNA in the absence of IgG in the
acute specimen. Seven of these children had a clinical diagnosis
of roseola and a further 6 had a clinical diagnosis of a viral
syndrome without a confirmed alternative microbiologic di-
agnosis (table 2). Only one 7-month-old child had a confirmed
alternative diagnosis (parainfluenza croup). This patient also
had HHV-6 DNA detectable in the plasma and a high viral
DNA load in the blood. A follow-up blood specimen obtained
20 weeks later showed that he seroconverted to HHV-6 during
this period.
In contrast, of 75 patients 13 months of age who had HHV-
6 IgG present in the acute plasma (HHV-6 DNA/IgG profile
suggestive of past infection) or were HHV-6 DNA– and IgG-
negative (HHV-6 DNA/IgG profile of no infection), none had
roseola, while 55 (73%) had a confirmed alternative microbi-
ologic diagnosis.
Seventeen of the 89 patients had HHV-6 DNA detected in
their plasma (table 2). Seven of these patients had clinical ro-
seola, and all of them had detectable HHV-6 DNA in the ab-
sence of IgG (the profile hypothesized to be associated with
primary HHV-6 infection). Seven other patients had HHV-6
IgG in the acute blood specimen (the profile hypothesized to
indicate past infection), none of whom had roseola, but 5 had
alternative microbiologic diagnoses (respiratory syncytial virus,
1; influenza A, 2; pneumococcal infection, 1; parainfluenza, 1).
Three of the 5 patients with alternative diagnoses had HHV-6
DNA loads 13.3 log10/5 mL of whole blood.
Saliva specimens. Twenty-four of the 33 saliva specimens
collected at initial presentation provided adequate specimen
volume for study. All 11 specimens collected from patients
whose whole blood was HHV-6 DNA–positive in the absence
of IgG had no detectable HHV-6 DNA in saliva, whereas 7 of
8 specimens from patients who were seropositive at initial pre-
sentation had detectable HHV-6 DNA in their saliva. Of 5
patients negative for both HHV-6 DNA and IgG in blood,
none had viral DNA in saliva.
Demographic data of the overall study population. When
the HHV-6 DNA/IgG profile of the acute blood specimen was
applied to the whole study population of 143 children, primary
HHV-6 infection was diagnosed in 39 (27%) of the patients
overall (under the age of 3 years) and 33 (50%) of the 66 patients
under the age of 1 year. The demographic data on the study
population with and without primary HHV-6 infection, re-
spectively, were as follows: male-to-female ratio, 1.3:1 versus
1.3:1; median age, 7.4 versus 14.7 months ( ). Twenty-P ! .001
eight (72%) of the 39 children with laboratory evidence of pri-
mary HHV-6 infection had clinical roseola.
Of the 143 children, an alternative diagnosis was documented
in 66, only 1 of whom had the HHV-6 DNA/IgG profile of
primary infection. The alternative microbiologic diagnoses were
influenza A and B, adenovirus, respiratory syncytial virus, par-
ainfluenza viruses, bacteremia, Salmonella, rotavirus, Campy-
lobacter jejuni, Branhamella pneumonia, urinary tract infection,
and herpangina.
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Table 2. Comparison of HHV-6 DNA/IgG profile and plasma DNA results in patients 13 months old (n 5 89) with
single blood specimens.
HHV-6 DNA/IgG profile in acute specimen
Plasma DNA in
acute specimen Roseola
Undiagnosed
viral fever
Alternative microbiologic
diagnosis
DNA-positive/IgG-negative (primary HHV-6 infection) Positive 7 2 1a
DNA-positive/IgG-negative (primary HHV-6 infection) Negative 0 4 0
IgG-positive (past HHV-6 infection) Positive 0 2 5
IgG-positive (past HHV-6 infection) Negative 0 13 33
DNA- and IgG-negative (no past HHV-6 infection) Negative 0 6 16
NOTE. Parentheses indicate hypothesized interpretation of HHV-6 DNA/IgG profile.
a Croup associated with parainfluenza type 3. Subsequent convalescent serum showed seroconversion to HHV-6.
Discussion
To validate the diagnostic options under investigation, our
initial analysis focused on patients 13 months of age with paired
blood specimens ( ), and we used seroconversion as then 5 42
reference standard to define primary HHV-6 infection. Serology
and PCR for HHV-7 were also done in parallel, because this
antigenically related virus may confound interpretation of
HHV-6 serology.
Detection of viral DNA in acute whole blood specimens had
a low positive predictive value (57%) for primary HHV-6 in-
fection, because viral DNA persists in PBL for many months
or years after primary infection. However, a positive viral DNA
result in whole blood combined with the lack of IgG antibody
in the corresponding plasma specimen proved to be a reliable
indicator of primary HHV-6 infection, with excellent sensitivity,
specificity, and positive and negative predictive values. The
value of the HHV-6 DNA/IgG profile is further supported by
the data from patients (13 months of age) from whom only
acute blood was available (table 2). While 72% of patients with
a DNA/IgG profile of past HHV-6 infection had microbiolog-
ically confirmed alternative diagnoses, only 1 of 14 patients
with a profile of primary infection had an alternative diagnosis.
The latter patient had seroconverted to HHV-6 when recalled
for convalescent blood sampling 20 weeks later, and he prob-
ably had concurrent infection with both HHV-6 and parain-
fluenza virus.
In a study in which sequential specimens of PBL, plasma,
and saliva were studied in 3 patients with serologically proven
primary HHV-6 infection, Suga et al. [15] found that viral DNA
appears in saliva only during convalescence. In a subsequent
study, others [10] have suggested that detection of HHV-6 DNA
in PBL in the absence of viral DNA in the saliva may be used
to diagnose primary HHV-6 infection. The latter study had no
independent confirmation (e.g., seroconversion or viral culture)
of primary HHV-6 infection, and conclusions were based on
only 3 patients. Our study supports the contention that the
absence of viral DNA in the saliva in the presence of HHV-6
DNA in the peripheral blood indicates primary HHV-6 infec-
tion. It must be noted, however, that more data need to be
collected in this regard and also that saliva is a less readily
standardized clinical specimen. These results also suggest that
primary HHV-6 infection is initially a systemic infection, with
the virus localizing to the salivary glands during convalescence.
The quantitative estimation of viral DNA in whole blood
and plasma specimens from patients with HHV-6 seroconver-
sion or past infection is shown in figures 1 and 2. Precautions
to minimize bias from interexperimental variation on the com-
parison of virus load between acute versus convalescent spec-
imens and primary versus past infections were taken. Viral
DNA load in whole blood of patients with HHV-6 serocon-
version was clearly higher than that of patients with past in-
fection. A previous preliminary report [10] based on 3 patients
had similar results. To exclude age-related bias, we quantified
virus load in 6 other patients (mean age, 8 months) from whom
only single specimens were available, who were viral
DNA–positive in the screening PCR assay, and who were HHV-
6 IgG–positive. All 6 had viral DNA loads of ≤3.3 log10 (data
not shown). We conclude that virus load may be used for di-
agnosing primary HHV-6 infection in the acute blood specimen.
There are only two other reports on HHV-6 load in primary
HHV-6 infection [9, 10]. Secchiero et al. [9] found virus loads
ranging from to /mL (0.48–3.5 log10/5 mL) in2 56 3 10 6 3 10
serum in 6 patients with exanthem subitum. Eighteen of our
19 patients with primary HHV-6 infection had comparable vi-
rus loads (!2.8–3.8 log10/5 mL). Clark et al. [10] report virus
loads of 4.3–5.5 log10/10
6 PBL isolated from peripheral blood
of 3 patients with primary HHV-6 infection. Our virus load in
primary HHV-6 infection was determined on DNA extracted
directly from whole blood rather than on PBL isolated from
whole blood. The mean total leukocyte count in febrile children
with primary HHV-6 was /L, in contrast to /9 97.4 3 10 13 3 10
L in children with past HHV-6 infection (Chiu SS, Peiris M,
unpublished data). If our results are converted to virus load/
106 PBL (based on each patient’s total leukocyte count), they
range between 4.9 and 16.5 log10, that is, ∼10-fold higher than
that reported by Clark et al. [10]. Similarly, their data for chil-
dren with past infection show a lower virus load (2.5–3.9 log10)
than ours (!3.8–4.7 log10). The separation of PBL before ex-
traction of the viral DNA (rather than direct extraction from
whole blood) may contribute to some of this difference in virus
loads between our results and those previously reported [10].
We have preliminary evidence that separation and washing of
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PBL before DNA extraction results in lower virus loads (Peiris
M, Cheung CY, unpublished data).
Other published data on HHV-6 load pertain to healthy
adults [16, 17] or human immunodeficiency virus–infected pa-
tients [18] and are not comparable with those for our patient
group. When we examined blood from healthy adults, HHV-6
loads were !2.8 log10/5 mL (i.e., ! /10
6 PBL) and clearly41.8 3 10
lower than those found in infants with past infection (Peiris M,
Cheung CY, unpublished data). Previously published HHV-6
loads in healthy volunteers have ranged between and13 3 10
/106 PBL [17], but HHV-6 load was as high as34 3 10
/mg of DNA (i.e., ∼ /106 PBL) in 1 person [16].6 61.2 3 10 10 3 10
When virus load data from different studies are compared, the
methods of extracting the DNA, the methods of isolating the
PBL (some leukocyte separation methods isolate only mono-
nuclear cells while others also isolate granulocytes), and the
patient populations must be considered.
Detection of HHV-6 DNA in the plasma has been proposed
as a means of diagnosing primary infection in the early stage
of the illness [8, 9], although the data supporting this assertion
are sketchy. Among the 42 patients 13 months of age from
whom paired blood was available, the sensitivity of detecting
HHV-6 DNA in the plasma for diagnosing primary HHV-6
infection was 90%. The lower sensitivity of plasma DNA is
explained by the lower virus load found in plasma compared
with whole blood (figure 2). Only 1 convalescent plasma spec-
imen (36 days after infection) remained HHV-6 DNA–positive,
suggesting that HHV-6 DNA in plasma does not persist, in
contrast to that in leukocytes.
While none of the 18 patients with past infection had de-
tectable HHV-6 DNA in the acute plasma specimen, 1 of their
convalescent plasma specimens was positive for HHV-6 DNA.
This 2-year-old patient had an alternative diagnosis of influenza
A. Furthermore, 7 other patients without paired specimens had
detectable plasma DNA associated with an HHV-6 DNA/IgG
profile suggestive of past infection; 5 of them had alternative
microbiologic diagnoses (table 2). Four of these children had
viral DNA loads usually associated with primary infection (i.e.,
≥3.8 log10). It is possible that reactivation of HHV-6 in response
to another infection may lead to detectable HHV-6 DNA in
the plasma as well as a high viral DNA load in whole blood.
Given these results, the true positive predictive value of a pos-
itive HHV-6 DNA result in plasma for primary HHV-6 infec-
tion must be !100%. Presumptive evidence of other viruses
stimulating HHV-6 reactivation in immunocompetent children
has been previously reported [4]. The fact that HHV-6 DNA
in the plasma may be associated with reactivation of HHV-6
in the immunocompromised patient is already recognized [13].
Definitive laboratory markers of viral reactivation, however,
are still awaited.
Three of 5 patients under 3 months of age with clinical and
virologic evidence of primary HHV-6 infection (high HHV-6
DNA load and plasma DNA–positive) failed to show a sero-
logic response. This may be due, in part, to the suppressive
effect of residual maternal antibody (below the level of detection
in our fluorescent antibody assay) on the immune response, as
has been reported for some vaccines [19]. The effect of passively
transferred maternal antibody in suppressing serologic re-
sponses to primary HHV-6 infection has been alluded to before
[4]. Two of the patients without a serologic response to HHV-
6 had detectable HHV-7 antibody in the acute plasma specimen
(in the absence of HHV-7 DNA), and these titers became un-
detectable in the convalescent specimen. It is possible that pas-
sively acquired cross-reactive HHV-7 antibody may dampen the
immune response to HHV-6 without offering protection. Al-
ternatively, the poor immune response may be due to the im-
maturity of the immune system of the young infant. It is pos-
sible that a serologic response may have been detected if blood
specimens later in convalescence were tested and more sensitive
methods were used. In our study, the 6-week-old child who
seroconverted did so late and only to low titer, in marked con-
trast to older children, who developed brisk and high antibody
responses. It is reported that the switchover from IgM to IgG
antibody production is delayed in neonates [19]. We looked
only for IgG antibody in our patients, and it may well be that
these infants produced good IgM responses. It may also be
interesting to dissect out the immune response to individual
viral antigens by using Western blot antibody assays in these
patients.
All of those patients with a serologic response to HHV-7 also
had definite evidence of concurrent HHV-6 infection. The
HHV-7 serologic responses in the other 11 patients are pre-
sumed to be cross-reactive antibody generated by HHV-6
infection.
A number of factors discussed above may potentially con-
found the use of the HHV-6 DNA IgG profile as a marker of
primary infection. If the profile of HHV-6 DNA–positive/IgG
antibody–negative is observed in an immunocompetent child
of any age, the interpretation is that of primary HHV-6 infec-
tion. However, a profile of DNA positive/IgG positive may
potentially be falsely interpreted as past infection, because of
either passive maternal antibody in the young child, cross-re-
acting HHV-7 antibody, or the early development of a primary
HHV-6 antibody response. In this study, the confounding effect
of HHV-7 cross-reactivity on the HHV-6 DNA/IgG profile did
not pose a problem in children 13 months old. This is probably
because HHV-7 infection occurs later in life than HHV-6 in-
fection. It would be predicted that the DNA/IgG profile may
not be reliable for the diagnosis of HHV-7 infection, and this
indeed is what we observed. It is the consensus of most inves-
tigators that specimens collected early in the course of HHV-
6 infection are seronegative or have low levels of antibody [15].
We have attempted to minimize the effect of early low-level
antibody responses by screening at a dilution of 1/50 and by
detecting only IgG class antibody. The HHV-6 DNA/IgG pro-
file is validated only within 5 days of disease onset.
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In patients with undifferentiated febrile illness, primary
HHV-6 infection was responsible for 50% of hospital admis-
sions under the age of 1 years. This incidence is somewhat
higher than that reported in other studies [4], and this may be
partly due to the fact that the emergency department in our
hospital is not staffed by pediatricians and may have a lower
threshold for hospitalizing infants. However, it does emphasize
the disease burden caused by this virus. Methods for rapid
diagnosis could contribute significantly to clinical management,
could help allay parent anxiety, and would probably be cost-
effective.
In conclusion, we document that an HHV-6 DNA/IgG profile
of positive viral DNA in whole blood associated with negative
IgG is a sensitive and specific method for the diagnosis of
primary HHV-6 infection in the acute (i.e., within 5 days of
onset) blood specimen. However, a DNA/IgG profile of past
infection in children under the age of 3 months must be treated
with caution. The detection of plasma DNA is an acceptable,
albeit less sensitive, approach to diagnosing primary HHV-6
infection. However, it may not differentiate between primary
infection and virus reactivation in response to an unrelated
infection. HHV-6 DNA load in whole blood differentiates be-
tween active and past HHV-6 infection, although again, this
may not discriminate between primary infection and reacti-
vation. The virus load assays as used in this study are not
applicable in routine clinical practice in their present form, but
we are presently developing assays that measure virus load in
a format more usable in the routine clinical laboratory.
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